GlassScriptPhysician profile
Melissa Belanger
NPI 1396046561
$9,645.53
in general payments reported to CMS, 2019-2025
22 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,878 · 2022: $2,547 · 2023: $1,912 · 2024: $2,021 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,142 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,141.79 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,729.77 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,633.29 | 2022-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $1,531.08 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $1,007.97 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $724.48 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $552.63 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $425.34 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $396.83 | 2021-2022 | |
| Alkermes, INC. | $333.30 | 2022-2024 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $274.66 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $210.80 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $195.90 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $143.52 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $119.58 | 2022-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $91.43 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $89.20 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $69.77 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $52.12 | 2022-2025 | Quviviq |
| Pear Therapeutics (US), INC. | $18.70 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.19 | 2022 | |
| Lilly USA, LLC | $14.82 | 2021 | |
| Eisai INC. | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Belanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.